Trial Profile
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs Samelisant (Primary)
- Indications Narcolepsy
- Focus Therapeutic Use
- Sponsors Suven Life Sciences
- 19 Oct 2023 Status changed from active, no longer recruiting to completed.
- 01 Jun 2023 Planned End Date changed from 1 Apr 2023 to 1 Jun 2023.
- 01 Jun 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Jun 2023.